News

Obsidian Therapeutics to Present Preclinical Data from cytoDRiVE® Platform and Pipeline at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022

November 7, 2022

Read More

Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb

October 27, 2022

Read More

Obsidian Therapeutics to Present at Upcoming Scientific Conferences

October 13, 2022

Read More
ABOUT US

We are pioneers in cell and gene therapy

Leading the next generation of engineered therapeutics

Read More

Our Platform

Our proprietary
cytoDRiVE platform

Leverages drug responsive domains (DRDs) to control protein function using an FDA-approved small molecule

Read More

OBSIDIAN CAREERS

Join Our Team

Join our collaborative team of innovators who are motivated by a sense of urgency to help patients in need.
Our collective knowledge, capabilities, intellect and energy is our greatest strength.

 

Read More